Biopharma Market Fuels South Korean Growth Engine
South Korea is the tenth largest economy in the world with a population of 51.3 million. Alongside fast growth of the region’s technology-driven economy, its pharma industry has been expanding significantly too.
You may also be interested in...
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
An ICH guideline describes the “weight of evidence” criteria that in some cases may provide an adequate assessment of human carcinogenicity risk without the need for data from a two-year rat carcinogenicity study.